Kolibri Global Energy (NASDAQ: KGEI)

(NASDAQ: KGEI) 

Kolibri Global Energy Inc. is a North American energy company focused on finding and exploiting energy projects in oil and gas. Through various subsidiaries, the Company owns and operates energy properties in the United States. The Company continues to utilize its technical and operational expertise to identify and acquire additional projects in oil and gas. The Company's shares are traded on the Nasdaq under the stock symbol KGEI, and on the Toronto Stock Exchange (TSX) under the stock symbol KEI.

Newton Golf (NASDAQ SPGC)

NASDAQ: SPGC

NEWTON GOLF (Nasdaq: SPGC)  is a technology-forward golf company that helps golfers elevate their game. With a growing portfolio of golf products, including putters, golf shafts, golf grips, and other golf-related accessories, the Company’s innovative accomplishments encompass the First Vernier Acuity putter, patented Ultra-Low Balance Point (ULBP) putter technology, weight-forward Center-of-Gravity (CG) design, and pioneering ultra-light carbon fiber putter shafts.

In consideration of its growth opportunities in golf shaft technologies, the Company expanded its manufacturing business in April of 2022 to develop the advanced Newton brand of premium golf shafts by opening a new shaft manufacturing facility in St. Joseph, MO. It is the Company’s intent to manufacture and assemble substantially all products in the United States, while also expanding into golf apparel and other golf-related product lines to enhance its growth.

The Company’s future expansions may include broadening its offerings through mergers, acquisitions, or internal developments of complementary product lines to its premium brand. The Company currently sells its products through resellers, its websites, Club Champion retail stores, and distributors in the United States, Japan, and South Korea.

New Era Helium (NEH)

NASDAQ: NEHC

Founded in 2023, New Era Helium, Inc. (NEH) is a helium exploration and production company operating 137,000 acres in New Mexico, with 1.5 billion cubic feet (BCF) of helium reserves. Our goal is to secure 1% of the North American helium market, aiming to be a key player in the distribution of helium across North America.  With plant construction underway and completion expected in Q2 2025, New Era Helium is strategically positioned to generate three revenue streams—helium, natural gas, and natural gas liquids—and to become a strong platform for consolidating start-up exploration and midstream players, driving growth and operational synergy.

MUSQ Music Industry ETF (NYSEARCA: MUSQ)

The MUSQ Global Music Industry ETF (MUSQ) offers investors focused exposure to the growing global music industry. The fund aims to replicate the performance of the MUSQ Global Music Industry Index (MUSQIX), which rebalances quarterly and includes publicly traded companies and royalty funds with significant revenues tied to music. MUSQ provides access to key segments such as music streaming, live events and ticketing, content distribution, satellite and broadcast radio, and music equipment and technology. Launched in July 2023, the fund is positioned to benefit from the evolving digital landscape, including the rise of streaming and AI-driven content creation.

With the global music industry projected to grow significantly in the coming years, MUSQ is an attractive vehicle for investors seeking to capture long-term growth trends in this dynamic sector. The ETF invests in companies that are integral to the modern music ecosystem, providing thematic and technology-driven exposure in a diversified, global format.

Alternus Clean Energy, Inc. (ALCE)

Alternus Clean Energy is a forward-thinking utility-scale clean energy independent power producer that effectively leverages transatlantic markets to amplify its impact and create value for shareholders. With a strategic focus on solar, battery storage and microgrids, Alternus has a robust portfolio and pipeline featuring operational and projects in development across America and Europe, backed by long-term power purchase agreements that ensure stable revenue streams.

Abacus Life (NASDAQ: ABL)

NASDAQ: ABL

Abacus Life, Inc. operates as an alternative asset manager and market maker in the United States. It operates through three segments: Portfolio Servicing, Active Management, and Originations. The Portfolio Servicing segment provides policy services to customers on a contract basis. The Active Management segment is involved in buying, selling, and trading policies, as well as maintaining policies until receipt of death benefits. The Originations segment originates life insurance policy settlements between investors or buyers, and the sellers, who is often the original policy owner. The company sells its products through financial advisor or agent, direct to consumer, and traditional life settlements intermediaries. Abacus Life, Inc. was founded in 2004 and is headquartered in Orlando, Florida.

Abeona Therapeutics Inc. (NASDAQ: ABEO)

NASDAQ: ABEO

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

ACCESS Newswire, Inc. (formerly IssuerDirect) NASDAQ ACCS

Actelis Networks, Inc. (NASDAQ: ASNS)

NASDAQ: ASNS

Secure Connectivity Solutions for Fast Expansion of IoT Networks

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN: ATNM)

NYSEAMERICAN: ATNM

Actinium develops Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML), which Actinium is seeking a potential strategic partner for in the U.S. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP)

NASDAQ: ACXP

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).

AgriForce AGRI

ABOUT AGRIFORCE AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) is dedicated to revolutionizing agriculture and food systems through innovative technology and sustainable practices. By integrating intellectual property, advanced technology, and deep industry expertise, AgriFORCE delivers solutions that drive value for shareholders and the communities it serves. Learn more at www.agriforcegs.com.

AiEnglishGPT

AiEnglishGPT is a one-of-a-kind education artificial intelligence which offers human- like A.I. teachers having natural conversation in real time, in any country, and in any of 63 languages.

The Ai will teach popular topics such as Upskill Training, Job Skill Training, Test Prep, Languages, Reading, Computer Sciences, Ai Engineering and Intervention Instruction other topics in high demand internationally.

Actual examples of the Super Teachers

In the background, the A.I. ”brain” is capturing and analyzing learning data from millions of users. This fuels the A.I.’s ability to further create never-seen-before individualized content for each individual learner.

AiEnglishGPT’s CEO, Mark Emerson said, “People can now work and learn independently, as preferred by many. AiEnglishGPT understands this market shift and our company has positioned itself to capitalize on this modern-day change within education across the globe.”

Emerson continued, “The proprietary A.I. has hundreds of independent engines creating interactive, multi-lingual instruction sessions that will bring a more effective, affordable and personalized instruction direct to learners’ devices”.

Alico, Inc.

Alico, Inc. is a holding company, which engages in the operations of agriculture, land management, and natural resources. It operates through the Alico Citrus, and Land Management and Other Operations segments. The Alico Citrus segment cultivates citrus trees to produce citrus for delivery to the processed and fresh citrus markets. The Land Management and Other Operations segment offers land leasing for recreational and grazing purposes, conservation, and mining activities. The company was founded on February 29, 1960 and is headquartered in Fort Myers, FL

Allysta (Private)

Allysta Pharmaceuticals is a private venture-backed clinical stage biopharmaceutical focused on rare diseases with high unmet needs. We are developing first-in-class therapeutic peptides with multiple biological actions, including anti-fibrotic, anti-inflammatory, cell regenerative, and beneficial metabolic effects that provides development opportunities across multiple diseases.  Our lead drug, ALY688ER, an extended release formulation designed for extended delivery of ALY688 throughout the body, is a potent and specific activator of adiponectin signaling pathways. Adiponectin is a beneficial cytokine produced mainly by adipose cells and which protects against obesity-associated diseases. ALY688 is the first adiponectin receptor agonist to enter human testing. Our lead indication is Duchenne muscular dystrophy (DMD), a serious rare genetic disease of boys in which muscle tissue damage due to muscle cell injury, inflammation and replacement of muscle by fibrotic tissue results in progressive loss of skeletal muscle function. In relevant animal DMD models, ALY688 reduced muscle cell death, enhanced muscle regeneration, and reduced inflammation and fibrosis, resulting in preservation of muscle strength and endurance.

In addition, ALY688 has shown similar benefits across a range of other inflammatory and fibrotic conditions potentially expanding its use in additional indications.

Amesite Inc. NASDAQ AMST

Amesite's smart, intuitive learning environments help organizations thrive. Businesses, Universities, Non-Profits and Government Agencies use our platform to launch branded learning programs with ease. Amesite’s customers receive branded, turnkey systems that scale out-of-the-box and can integrate 1000s of APIs – giving them the optimal combinations of integrations for their organization. Amesite-built courses and programs are available for organizations to use. Amesite ecosystems can launch for our customers in as little as 24h.

AsiaFIN Holdings Corp ASFH

ASFH is a US listed (OTC:ASFH), fintech financial ecosystem enabler based out of Malaysia with corporate customers in 8 countries in Asia.

ASFH delivers regtech and RPA solutions and system integration services. ASFH plans to expand into the Middle East and the USA in 2025-2026.

Azitra, Inc. NYSEAMERICAN: AZTR

Azitra, Inc. NYSEAMERICAN: AZTR

Azitra is a pioneer in genetically engineered bacteria and proteins for therapeutic use in dermatology. Azitra leverages proprietary platforms and an internal microbial library to create new therapeutics that are either engineered living organisms or engineered proteins or peptides to treat skin diseases. Azitra has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts, and helps screen Azitra’s library of strains for drug like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains. Azitra’s initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis. Azitra’s lead therapeutic candidates are ATR-12, a genetically modified strain of S. epidermidis for treating the orphan disease Netherton syndrome, and ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor, or EGFRi, targeted therapy.

Baird Medical NASDAQ: BDMD

Barksdale Resources OTCMKTS BRKCF

Barksdale is committed to increasing shareholder value by acquiring, exploring, and de-risking high quality precious and base metal projects in the Americas. We operate under a simple philosophy that requires a disciplined approach to buying well and conducting thorough and systematic exploration. Underpinning this philosophy is a focus on obtaining assets that provide the appropriate mix of exploration potential, district scale property control, and optionality around potential exits.

Better Home & Finance (BETR)

Since 2017, Better Home & Finance Holding Company (NASDAQ: BETR; BETRW) has leveraged its industry-leading technology platform, Tinman™, to fund more than $100 billion in mortgage volume. Tinman™ allows customers to see their rate options in seconds, get pre-approved in minutes, lock in rates and close their loan in as little as three weeks. Better’s mortgage offerings include GSE-conforming mortgage loans, FHA and VA loans, and jumbo mortgage loans. Better launched its “One Day Mortgage” program in January 2023, which allows eligible customers to go from click to Commitment Letter within 24 hours. Better was named Best Online Mortgage Lender by Forbes and Best Mortgage Lender for Affordability by WSJ in 2023, ranked #1 on LinkedIn’s Top Startups List for 2021 and 2020, #1 on Fortune’s Best Small and Medium Workplaces in New York, #15 on CNBC’s Disruptor 50 2020 list, and was listed on Forbes FinTech 50 for 2020. Better serves customers in all 50 US states and the United Kingdom.

BIO-key International, Inc.

BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.

BitFuFu Inc FUFU

 BitFuFu Inc. is a global leader in Bitcoin mining and comprehensive mining services, providing customers with one-stop solutions, including Cloud mining. BitFuFu received early investments from BITMAIN, a world-leading digital asset mining hardware manufacturer, and remains BITMAIN's strategic partner in the Bitcoin mining and mining services space.

BitFuFu is dedicated to fostering a secure, compliant, and transparent blockchain infrastructure and providing a variety of stable and intelligent digital asset mining solutions to a global customer base. Leveraging its expanding global mining facility network and strategic partnership with BITMAIN, BitFuFu enables institutional customers and digital asset enthusiasts to mine digital assets efficiently.

C6 Capital, LLC

CareCloud, Inc NASDAQ: CCLD

NASDAQ: CCLD

CareCloud is a healthcare information technology company that offers comprehensive software and services to help medical groups increase revenue, streamline workflow, and modernize the patient experience. CareCloud offers the most diverse suite of software and services designed to help providers transform and improve their clinical, financial, and administrative operations.

CEL-SCI Corporation NYSEAMERICAN: CVM

CEL-SCI Corporation NYSEAMERICAN: CVM

CEL-SCI Corporation (NYSE MKT: CVM), a biotechnology company, was formed in 1983. CEL-SCI is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. The Company's core capabilities include: drug discovery, research, development and manufacturing of complex biological substances.

If you would like to share your feedback with us via e-mail, we invite you to send us your comments or letters to Feedback@cel-sci.com.

Citius Pharmaceuticals, Inc. CTXR

Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR™, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs.

Comstock, Inc.NYSEAMERICAN: LODE

Comstock, Inc. NYSEAMERICAN LODE

Comstock commercializes technologies that enable systemic decarbonization and accelerate the energy transition by efficiently converting under-utilized natural resources into renewable energy products, and by leveraging physics based artificial intelligence for more efficient and effective mineral and materials discovery.

Corero Network PLC

Corero Network Security is the leading DDoS protection specialist listed on the AIM market of the London Stock Exchange (AIM: CNS) as well as the US OTC Market (OTCQX: DDoSF). Corero provides best-in-class automatic detection and protection DDoS solutions with network visibility, analytics, and reporting tools. Corero’s technology protects against external and internal DDoS threats in complex edge and subscriber environments, ensuring internet service availability. Headquartered in London, Corero has operational centers in Massachusetts, USA, and Edinburgh, UK.

DarioHealth NASDAQ DRIO

DarioHealth NASDAQ DRIO

DarioHealth Corp. is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

Our user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and results.  Making the right thing to do the easy thing to do

Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers.  To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.

Diagnos Inc OTCMKTS DGNOF

Diagnos Inc OTCMKTS DGNOF

We work closely with public or parapublic organizations such as governments at all levels to scan their population, to prevent serious consequences on the health of its population. Diagnos enables the deployment of the CARA solution and connect patients from health clinics and pro with minimal effort from specialists and clinics. We take care of you so that you can take care of your patients.

Duos Technologies Group, Inc. DUOT

Duos Technologies Group, Inc. (Nasdaq: DUOT), based in Jacksonville, Florida, through its wholly owned subsidiaries, Duos Technologies, Inc., Duos Edge AI, Inc., and Duos Energy Corporation designs, develops, deploys, and operates intelligent technology solutions for Machine Vision and Artificial Intelligence (“AI”) applications including real-time analysis of fast-moving vehicles, Edge Data Centers and power consulting. For more information, visit www.duostech.com,  www.duosedge.ai, and www.duosenergycorp.com.

DZS OTCMKTS DZSI

DZS OTCMKTS DZSI

DZS is a global leader of Network Edge, Connected Home/Enterprise and AI Cloud Software solutions that enable gigabit broadband everywhere.

Ethema Health Corporation OTCMKTS: GRST

Ethema Health Corporation OTCMKTS: GRST

Ethema Health Corporation (OTCQB: GRST), together with its subsidiaries, operates in the behavioral healthcare space specifically in the treatment of substance use disorders. With a seasoned management team, Ethema strives to develop world-class “centers of excellence” in addiction treatment for adults. The Company currently operates in West Palm Beach, Florida.

FendX Technologies Inc

At the intersection of healthcare and advanced materials, FendX is dedicated to advancing products under development using its innovative nanotechnology to keep surfaces safe from contamination. Products in development include a film and nano-particle solution that have been shown to significantly reduce the adhesion and transmission of bacteria and viruses. REPELWRAP™ film is currently in real-world beta-testing and the solution is in the formulation phase. FendX is also using its novel nanotechnology to develop nano-coated catheter protypes to minimize blood clots and bacterial biofilm formation. The Company conducts R&D in collaboration with industry-leading partners, including McMaster University, and has exclusive worldwide licenses to its nanotechnology from McMaster. FendX is also actively pursuing additional in-licensing and acquisition opportunities to expand its infection disease control product portfolio and enhance its impact in protecting surfaces. Recently, FendX signed a letter of intent (LOI) to acquire certain intellectual property as well as enter into a supply agreement for an eco-friendly foam pad that offers a sustainable surface cleaning solution and future potential as a wound care drug delivery platform.

Gaia Inc. NASDAQ GAIA

Gaia Inc. NASDAQ GAIA

We are Gaia. A global conscious media company committed to evolving consciousness by creating a transformational network that empowers a global conscious community. Our subscription service provides access to a vast content library that caters to a unique and underserved member base.

GameSquare Holdings (GAME)

GameSquare Holdings NASDAQ: GAME

GameSquare’s mission is to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Our next generation media, entertainment, and technology capabilities drive compelling outcomes for creators and maximize our brand partners’ return on investment. Through our purpose-built platform, we provide award winning marketing and creative services, offer leading data and analytics solutions, and amplify awareness through FaZe Clan, one of the most prominent and influential gaming organizations in the world. With an audience reach of 1 billion digitally native consumers across our media network and roster of creators, we are reshaping the landscape of digital media and immersive entertainment. 

GreenRise Foods

Controlled Environment Agriculture company that produces over 20 million pounds of tomatoes and mini sweet peppers annually. The fresh produce is sold to retailers such as Costco.

Health In Tech NASDAQ HIT

Health In Tech NASDAQ HIT

Health in Tech is an Insurtech platform company backed by third-party AI technology. We offer a dynamic marketplace designed to create customized healthcare plan solutions while streamlining processes through vertical integration, process simplification, and automation. By eliminating friction and complexities, HIT enhances value propositions for employers and optimizes underwriting, sales, and service workflows for Managing General Underwriters (MGUs), insurance carriers, licensed brokers, and Third-Party Administrators (TPAs).

Healthy Choice Wellness Corp HCWC

Healthy Choice Wellness Corp (NYSEAM: HCWC) is a U.S. based publicly traded company specializing in providing consumers with healthier alternatives to everyday lifestyle choices. Local. Organic. Fresh. Three words that define Healthy Choice Markets! Under its wholly owned subsidiaries, Healthy Choice Markets, Inc., Healthy Choice Markets II, LLC, Healthy Choice Markets III, LLC, Healthy Choice Markets IV, LLC, Healthy Choice Markets V, LLC and Healthy Choice Markets VI, LLC, HCWC owns and operates Ada's Natural Market, a. full-service grocery store, serving Fort Myers, FL, along with three (3) Paradise Health & Nutrition locations in the greater Melbourne, FL area, Mother Earth’s Storehouse in Hudson Valley, NY, eight (8) Green’s Natural Foods in New York and New Jersey States, Ellwood Thompson’s Local Market in Richmond, VA, and our newly acquired five (5) GreenAcres Market in Kansas and Oklahoma, all serving their respective local communities.

High Performance Battery Technology GmbH (Private)

HPB is a technology developer for innovative batteries. With the HPB Solid-State Battery, which offers safety, an enormous battery cycle life and up to 50% better environmental balance, a new basic technology for energy storage has been created. HPB Battery Technology is licensed to manufacturers and distributors worldwide by application and geography. These companies independently fulfill the demand for HPB Battery Technology in their fields of application and markets in order to shape the energy transition together and as efficiently as possible.

ImmunoPrecise Antibodies IPA

IPA is at the forefront of biotechnological innovation, transforming the fields AI and pharmaceutical research with its software LENSai, an Integrated Intelligence Platform, powered by their patented HYFTs patterns. This advanced Foundation AI model leverages AI to enhance drug discovery and data management processes. The integration of diverse biological data through HYFT technology allows for unparalleled analytical depth, accelerating research and development while revealing complex biological relationships. With LENSai's Foundation AI model our mission is aimed at uncovering breakthrough pharmaceutical solutions that are both safer and more effective. Join us as we lead the transformative era in life sciences.

Impact Biomedical Inc. IBO

Impact BioMedical Inc.(NYSE American: IBO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.

Kairos Pharma, Ltd. (KAPA)

Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs.

Massimo Group NASDAQ MAMO

Massimo Group NASDAQ MAMO

Imagine coming to a distant foreign land with about a hundred bucks in your pocket, a suitcase with just a few personal items and couple widgets you think might sell. Knowing no one, no job, no place to live and can’t speak the language. In fact, the ONLY thing you have is a dream.

It’s from these incredibly humble beginnings where the Massimo story truly begins. Learning real fast through hard work, practice and perseverance that people will and in fact want to buy, if your product quality is good, price is good, and service is good. This simple, yet hard earned statement...”Good Price, Good Quality and Good Service” is in fact our foundation at Massimo Motor.

NANO Nuclear Energy Inc. (NNE)

NANO Nuclear Energy (NASDAQ: NNE) is the 1st Vertically Integrated Advanced Portable Nuclear Microreactor publicly listed in the U.S. Under Mr. Yu's leadership, NANO Nuclear Energy reached over $1 Billion Market Capitalization in value, has raised approximately a total of $150 Million within 7 months of going public through a traditional IPO and became Wall Street's Cinderella story of 2024 as the #1 IPO Performer in the U.S. NANO Nuclear's team is led by world-class nuclear engineers, former USA National Leaders in Military and Policy, U.S. Department of Energy, National Laboratory, Nuclear Regulatory Experts developing Smaller, Cheaper, & Safer Advanced Portable Nuclear Microreactors for clean energy solutions & to help democratize energy for the world. 

About NANO Nuclear Energy

NANO Nuclear Energy Inc. (NASDAQ: NNE) is an advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable microreactor technology, (ii) nuclear fuel fabrication, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services. NANO Nuclear believes it is the first portable nuclear microreactor company to be listed publicly in the U.S.

Led by a world-class nuclear engineering team, NANO Nuclear’s products in technical development are “ZEUS”, a solid core battery reactor, and “ODIN”, a low-pressure coolant reactor, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.

Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, is led by former executives from the largest transportation company in the world aiming to build a North American transportation company that will provide commercial quantities of HALEU fuel to small modular reactors, microreactor companies, national laboratories, military, and DOE programs. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy. Assuming development and commercialization, AFT is expected to form part of the only vertically integrated nuclear fuel business of its kind in North America.

HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear’s own microreactors as well as the broader advanced nuclear reactor industry.

NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear’s developing micronuclear reactor technology in space. NNS is focusing on applications such as power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS’ initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon’s surface.

NanoViricides, Inc (NNVC)

NanoViricides, Inc (NYSE ticker: NNVC) is a Phase II-ready, clinical stage company developing broad spectrum, anti-viral therapeutics (not vaccines) to treat and potentially cure most viral diseases using its patented nanotechnology that is expected to be effective even as the virus mutates, and that does not rely on the patients immune system, unlike most of today's vaccines, antibodies and small chemicals.

The Company's lead drug NV-387 is effective against RSV, COVID, M-pox/small pox, and the FLU, the potential market size of which is well in excess of $10 billion.

This pre-revenue Company is at a major inflection point in Market Valuation because NV-387, the Company's lead drug, has just completed Phase I human clinical studies demonstrating excellent safety and tolerability. We are Phase II-ready for: advancing NV-387 into Phase II clinical trials for MPox in Central Africa; progressing NV-387 towards filing an IND with USA and India Regulators for Phase II clinical trials of RSV in adults, then infants and children.

The achievement of Phase II clinical trials will lead to a step jump in Market Valuation of the company and attract collaboration licensing opportunities with big pharma. Historically, antiviral drug companies with a Phase II asset have generated multi-billion licensing revenues for such one-off drugs stemming from platform technologies or attract acquisition of such assets.

Any investment in the company now would therefore be expected to deliver a high return on investment because a similar increase in Valuation is expected to occur every time the Company achieves subsequent milestones (eg. Phase III clinical trials) on the road to commercialization.

Nature's Miracle Holding Inc. NASDAQ NMHI

Nature's Miracle Holding Inc. NASDAQ: NMHI

Nature’s Miracle Holding Inc. (Delaware) is a vertically integrated controlled environment agriculture technology company. The Company operates multiple subsidiaries including our flagship Visiontech Group.

Ocean Power Technologies, Inc. (NYSEAMERICAN OPTT)

OPT is a leader in innovative and cost-effective low-carbon marine data, power, and consulting service solutions, with capabilities that allow for smarter and faster actionable insights.

ONAR (Private)

ONAR (OTCQB:RELT) is a leading marketing technology company and network of specialized marketing agencies. We blend AI-driven technology with human expertise to help middle-market and growth-stage companies drive revenue.

Panhwar Jet (Private)

Panhwar Jet is at the forefront of the burgeoning all-electric unmanned aircraft market, developing cutting-edge solutions for the rapidly growing global logistics sector. We are poised to capitalize on the significant market opportunity presented by the increasing demand for faster, more efficient, and sustainable transportation solutions. 

Perfect Corp (PERF)

Perfect Corp. (NYSE: PERF), founded in 2015, is the AI powerhouse for beauty and fashion brands. We develop 'Beautiful AI' innovations, including Beauty AI, Skin AI, Fashion AI, and Generative AI SaaS solutions. We lead in assisting top beauty brands in digital transformation, enhancing customer engagement, and driving sales growth while prioritizing sustainability and social responsibilities.

PetVivo Holdings Inc. PETV

About PetVivo Inc: PetVivo Inc. is based in Minneapolis, Minnesota. It is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. PetVivo believes that it can leverage the investments in the human bio-materials and medical device industries to commercialize medical devices and therapeutics to pets in a capital and time efficient way. PetVivo's strategy is to internally develop and/or in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PodcastOne, Inc. (NASDAQ: PODC)

PodcastOne is a Los Angeles-based leading podcast network providing creators and advertisers with a full 360-degree solution in sales, marketing, public relations, production, and distribution. With a community of 200 top podcasters and content covering all verticals (i.e. sports, entertainment, true crime, business, self-growth, etc.), we provide a platform of engaging content for brands to reach their most sought after audiences. We are also the parent company of LaunchpadOne, an innovative self-serve platform developed to launch, host, distribute and monetize independent user-generated podcasts. PodcastOne has built a distribution network that includes parent company LiveOne, Spotify, Apple Podcasts, Amazon, iHeartRadio, YouTube, and more to become one of the top podcast networks and the only publicly traded pure-play podcast company in the United States.

Radiance BioPharma

Radiance BioPharma is a privately held biotech company developing Antibody Drug Conjugates Our lead drug, RB-164 we are planning a phase I clinical trial for 2025.

Red CatNASDAQ: RCAT

Red Cat NASDAQ: RCAT

Red Cat (Nasdaq: RCAT) is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Through two wholly owned subsidiaries, Teal Drones and Flightwave Aerospace, Red Cat has developed a bleeding-edge Family of ISR and Precision Strike Systems including the Teal 2, a small unmanned system offering the highest-resolution thermal imaging in its class, the Edge 130 Blue Tricopter for extended endurance and range, and FANG™, the industry's first line of NDAA compliant FPV drones optimized for military operations with precision strike capabilities.  Learn more at www.redcat.red.

Reed's, Inc. (OTCQX: REED)

Established in 1989, Reed's is America's best-selling Ginger Beer brand and has been the leader and innovator in the ginger beer category for decades. Virgil's is America's best-selling independent, full line of natural craft sodas. The Reed's Inc. portfolio is sold in over 35,000 retail doors nationwide. Reed's Ginger Beers are unique due to the proprietary process of using fresh ginger root combined with a Jamaican inspired recipe of natural spices and fruit juices. The Company uses this same handcrafted approach in its award-winning Virgil's line of great tasting, bold flavored craft sodas.

RespireRx Pharmaceuticals Inc OTCMKTS RSPI

RespireRx Pharmaceuticals Inc OTCMKTS: RSPI

RespireRx Pharmaceuticals Inc. is a biopharmaceutical company developing innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling.

Sally's Apizza (Private)

As more people see the growth and success of our new locations, we are receiving an increasing amount of investment inquiries.

As a private growth company, securities in our company may only be offered through private placement. Securities in our Company may only be offered as a part of a private placement of securities under Rule 506(c) of Regulation D under the Securities Act of 1933 (the “Securities Act”). The Company may only sell securities to “accredited investors” as defined in Rule 501 of the Securities Act. Under Rule 506(c), the Company must take reasonable steps to verify that its investors are accredited investors, which means that prior to selling any securities to an accredited investor, any prospective investor will be required to verify and document that you qualify as an “accredited investor.”

This investment inquiry form does not constitute (1) offer to sell, or the solicitation of an offer to buy, any securities of Lineage Brands or any other Sally’s Apizza related entity, or (2) a representation that any offer will be made to the recipient or any other party.

I hereby certify that I am familiar with the definition of “accredited investor” as defined in Rule 501 of Regulation D issued pursuant to the Securities Act of 1933, as amended, and that I meet the criteria to qualify as an accredited investor, in the category or categories indicated below.

Scienture Holdings Inc. (SCNX)

SCIENTURE HOLDINGS, Inc is a comprehensive health services and pharmaceutical product company focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs, optimize the prescription journey and patient engagement in the U.S. Enhanced Value: Addressing underserved patients and indications through novel product concepts and innovation Deep Expertise: R&D, Product Development Research and Manufacturing know-how; Unique product pipeline and focused therapeutic area strategy Robust Commercial Operations: Complete suite of Sales and Marketing to include Branding, Promotion, Market Access and Distribution Accomplished leadership and management team: with many years of multidisciplinary experience and deep market knowledge Disruptive Innovation: Significantly lowers drug and health services costs utilizing our proprietary technology platforms Strategic Infrastructure: Well-developed, synergistic divisions ready for growth

Sensus Healthcare, Inc. (SRTS)

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive, and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy photon radiotherapy known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

Sequoia Vaccines Inc (Private)

We are Sequoia Vaccines, Inc., a clinical-stage pharmaceutical company focused on the discovery and development of novel vaccines to prevent bacterial infections including recurrent urinary tract infections (UTIs) and the treatment of certain cancers and lung infections associated with cystic fibrosis with small molecules.

Sky Harbour Group Corporation NYSEAMERICAN: SKYH

Sky Harbour is an aviation infrastructure development company building the first nationwide network of Home-Basing Solutions (“HBS”) for business aircraft. Sky Harbour develops, leases and manages general aviation hangars across the United States, targeting airfields in the largest growth markets with significant aircraft populations and high hangar demand. Sky Harbour’s HBS campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.

Soligenix, Inc. SNGX

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We have two areas of focus: 1) a specialized biotherapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, psoriasis, oral mucositis, Behçet’s disease, and pediatric Crohn’s disease. 2) a public health solutions segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure and viral disease including Ebola, Marburg and COVID-19.

Tau Lotus Inc

Alternative Energy Mobility Solutions product manufacturing company

Telvantis OTCMKTS RDAR

Telvantis (OTCMKTS RDAR) provides technology products and services to the telecommunication industry. With decades of experience, we have built a strong track record of serving the world’s leading telco operators, network providers, and enterprises. Our entrepreneurial background fuels our aspiration to stay at the cutting edge of innovation.

We are shaping the future of our industry with a bold vision and by leveraging our extensive commercial and technological platforms.

Tharimmune, Inc. THAR

Tharimmune, Inc. (Nasdaq: THAR) is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology and inflammation. The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.

The Metals Company TMC

The Metals Company (Nasdaq: TMC) is a developer of the world’s largest estimated undeveloped resource of battery metals for EVs, and the world’s #1 and #2 largest undeveloped nickel projects as ranked by Mining.com. TMC’s resource in the Clarion Clipperton Zone of the Pacific Ocean contains a very high concentration of nickel, copper, cobalt and manganese, with an estimated resource of 1.6 billion tonnes of nodules, sufficient to support the electrification of 280 million EVs, equivalent to the entire U.S. passenger car fleet. The resource is in the form of polymetallic nodules, which sit unattached on top of the seafloor, so nodule collection requires no blasting, no drilling and no digging. Nodule collection in the Clarion Clipperton Zone was successfully done on a pilot basis by four consortia in the 1970s, including BP, Shell, Rio Tinto, Sumitomo, Lockheed Martin and US Steel. TMC has successfully concluded its own pilot collection trial, lifting 3,000 tonnes to the Hidden Gem vessel in Q4 2022: https://vimeo.com/778303976/28d019f234 TMC's NORI-D area has an SEC S-K 1300 compliant technical report and initial assessment indicating an NPV of $6.8 billion representing just 22% of TMC’s total estimated resource.

The Real Brokerage Inc. NASDAQ: REAX

The Real Brokerage Inc. (Nasdaq: REAX) is revolutionizing the residential real estate industry by pairing best-in-class technology with the trusted guidance of an agent. We provide a digital brokerage platform for agents, while working to build a better end-to-end home buying experience for consumers.

TRX Gold Corporation NYSE-A: TRXTSX: TRX

TRX Gold Corporation NYSE-A: TRXTSX: TRX. TRX Gold is growing the Buckreef Gold project in Tanzania, consisting of a low-risk, high-margin open-pit gold mining operation and 2M+ ounces gold in M&I Mineral Resource* at the 16km2 property. The Company completed its 3rd mill expansion in July 2024 and expects to increase its annual gold production guidance for f2025. The Company is also exploration/brownfield drilling with the goal of increasing the Mineral Resource, and has a high-priority program set on its latest discovery, the Stamford Bridge Shear Zone. The Company is self-funded through consistent positive operating cash flow, is debt free and has not had to raise equity since 2021.

Universal Biosensors Inc UBI

Universal Biosensors (UBI) is a global biosensor company and world leader in Point of Use electrochemical sensing. UBI is a Delaware company which is listed on the Australian Stock Exchange (ASX:UBI). UBI has 20 years of experience developing, manufacturing, and delivering accurate and cost-effective analytical results from a portable handheld analyzer using a fingerstick of blood. Our history includes inventing, developing and: 1.partnering (with Johnson&Johnson “LifeScan”) one of the biggest blood glucose testing products (OneTouch Verio) which has sold more than 15 billion tests globally; 2.commercialising two generations of Point of Care coagulation PT/INR products (Xprecia) which monitor a patients PT/INR level within seconds, from a fingerstick sample (sold across 36 countries). US FDA 510(k) and CLIA Waiver approval received for Xprecia Prime in March 2024; 3.commercialising a portable handheld analyzer and 6 assays (Sentia) for the monitoring of six key compounds throughout the wine production process; 4.commercialising a veterinary blood glucose monitoring product (Petrackr) for managing cats and dogs with diabetes. UBI is developing a range of portable Point of Use monitoring products in oncology, fertility, environmental and water sensing including a portable handheld product for water utilities to identify lead and copper pipe infrastructure in drinking water systems.

Walk-in Dermatology (Private)

Walk-in Dermatology (Private). We’ve eliminated the wait time associated with seeing a dermatologist by using ultra-modern technology and same-day scheduling. We call this approach to our practice of medicine “convenient care.”

Whether you’re seeing us in-person at our modern office, or seeing us remotely via a Video Visit, our mission is to provide the best dermatological care in a setting that meets the needs of our patients.

WiSA Technologies, Inc. WISA

WiSA Technologies, Inc. (Nasdaq: WISA), which is in a definitive agreement to acquire AI, blockchain and Data Web 3.0 IP assets of Data Vault Holdings, Inc.® (“Data Vault”) to form a data technology & licensing company leveraging IP & proprietary HPC software.

XORTX Therapeutics Inc. (Nasdaq: XRTX)

XORTX Therapeutics, Inc. is a drug based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. Our focus on developing kidney therapies also includes therapeutics programs for large markets such as diabetic nephropathy and acute kidney injury associated with respiratory virus infections such as SARS-CoV-2.

We possess patents and patent applications that may include U.S. and international rights regarding the development of uric acid-lowering agents for the treatment of hypertension, insulin resistance, diabetes, metabolic syndrome, and kidney injury.

ZenaTech ZENA

ZenaTech (Nasdaq: ZENA) (FSE: 49Q) is a technology company specializing in AI drone, Quantum Computing, Drone as a Service (DaaS), and enterprise SaaS solutions for mission-critical business applications. Since 2017, the company has leveraged its software development expertise and grown its drone design and manufacturing capabilities through ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes. With enterprise software customers using branded solutions in law enforcement, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, ZenaTech’s portfolio of solutions helps drive exceptional operational efficiencies, accuracy and cost savings. The company operates through seven global offices in North America, Europe, Taiwan and UAE, and a growing global partner network.

Zhibao Technology Inc NASDAQ ZBAO

Zhibao Technology Inc NASDAQ: ZBAO. 2B2C(to-Business-to-Consumer) embedded digital insurance brokerage has evolved from a concept to a rapidly emerging market in Asia and across the globe.

Zhibao Technology Inc. has become the pioneer and market leader in the 2B2C embedded digital insurance solutions market in China.

Zivo Bioscience, Inc. OTCMKTS ZIVO

Zivo Bioscience, Inc. OTCMKTS: ZIVO. A U.S.-based R&D firm, is dedicated to the study, development and commercialization of natural nutritional compounds and bioactive molecules derived from proprietary algal strains.

ZJK Industrials Co. Ltd. NASDAQ ZJK

ZJK Industrials Co. Ltd. Nasdaq: ZJK. We are a high-tech enterprise specialized in manufacturing and sale of precision fasteners, structural parts and other precision metal parts products for new energy vehicles, circuit boards, data centers, liquid cooling systems for high-speed supercomputers widely applied in the artificial intelligence (“AI”) industry, and intelligent electronic equipment, such as mobile phones, smart watches, drones, and 5G communication base stations. 

Zomedica NYSEAMERICAN: ZOM

Zomedica NYSEAMERICAN: ZOM is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. An NYSE American company, Zomedica grew revenue 33% in 2023 to $25 million and maintains a strong balance sheet with approximately $78 million in liquidity as of September 30, 2024. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices.

Zoomcar Holdings IncNASDAQ: ZCAR

Zoomcar Holdings Inc Nasdaq: ZCAR, Founded in 2013 and headquartered in Bengaluru, India, Zoomcar is a leading marketplace for car sharing focused in India. The Zoomcar community connects Hosts with Guests, who choose from a selection of cars for use at affordable prices, promoting sustainable, smart transportation solutions in India. Zoomcar was listed on NASDAQ in 2023.

500 Performance LLC (Private)

At 500 Performance LLC (Private), we elevate the racing experience with our passion for custom builds. We believe in providing our clients with high-quality custom products tailored to their racing needs. Our team is dedicated to providing exceptional service and expertise. Join the winners at 500 PERFORMANCE and see what our team can do for your racing career. We specialize in airflow manipulation intakes and tailoring them to your engine so that you can take that checkered flag with confidence.